Healthcare Industry News: benign prostatic hyperplasia
News Release - June 23, 2006
Dr. Reddy's launches authorized generic versions of Proscar(R) and Zocor(R)HYDERABAD, India--(HSMN NewsFeed)--June 23, 2006--Dr. Reddy's Laboratories (NYSE:RDY ) today announced that it has launched the authorized generic version of Merck's ProscarŪ tablets 5mg (finasteride) on June 19, 2006. The Company has also launched the authorized generic version of Merck's ZocorŪ tablets (simvastatin) 5mg, 10mg, 20mg, 40mg and 80mg on June 23, 2006.
In January 2006, the Company entered into separate agreements with Merck that allowed it to launch the authorized generic versions of ProscarŪ tablets (finasteride) and ZocorŪ tablets (simvastatin). The specific financial terms and conditions of the agreement have not been disclosed.
About Dr. Reddy's
Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY ) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer.
Notes to the editor:
ProscarŪ is indicated for the treatment of benign prostatic hyperplasia with innovator sales of US$ 393 million (IMS December 2005 MAT). The compound patent for ProscarŪ expires on June 19, 2006. ZocorŪ is ZOCOR is indicated to reduce elevated LDL-C and TG levels in patients with Type IIb hyperlipidemia (where hypercholesterolemia is the major abnormality) with innovator sales of US$ 4.5 billion (IMS December 2005 MAT). The '784 compound patent for ZocorŪ expires on June 23, 2006.
Source: Dr. Reddy's Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.